Relative risk (95% confidence interval) | ||||
---|---|---|---|---|
Median value | Death (n = 26) | Heart failure (n = 56) | Unstable coronary syndrome (n = 65) | |
BNP (pmol/l) | 27 | 6.0 (2.1 to 16.9)*** | 5.0 (2.7 to 9.5)*** | 1.4 (1.0 to 2.2) |
ANF (pmol/l) | 30 | 2.8 (1.2 to 6.4)** | 5.4 (2.8 to 10.5)*** | 1.1 (0.7 to 1.6) |
N-ANF (pmol/l) | 1865 | 4.2 (1.6 to 10.7)*** | 3.3 (1.9 to 5.8)*** | 1.2 (0.8 to 1.9) |
cGMP (nmol/l) | 5.7 | 1.3 (0.6 to 2.8) | 3.3 (1.9 to 5.8)*** | 1.1 (0.8 to 1.7) |
Noradrenaline (nmol/l) | 1.94 | 0.9 (0.4 to 1.8) | 1.9 (1.2 to 3.1)** | 1.1 (0.7 to 1.7) |
Adrenaline (pmol/l) | 164 | 1.0 (0.5 to 2.1) | 1.8 (1.1 to 2.9)4-150 | 0.8 (0.5 to 1.2) |
LVEF (%) | 47 | 2.6 (1.1 to 5.9)4-150 | 3.4 (1.9 to 6.1)*** | 1.1 (0.7 to 1.7) |
LVEDV (ml) | 145 | 2.6 (1.1 to 5.9)4-150 | 2.1 (1.3 to 3.4)** | 0.9 (0.6 to 1.4) |
LVESV (ml) | 77 | 3.5 (1.4 to 8.3)** | 4.1 (2.3 to 7.6)*** | 1.0 (0.7 to 1.5) |
↵4-150 p < 0.05; **p < 0.01; ***p < 0.001 (χ2analysis).
For neurohormonal markers and left ventricular volumes, risk ratios were calculated from event rates above divided by rates below group medians, and for LVEF below/above the median.
ANF, atrial natriuretic factor; BNP, brain natriuretic peptide; cGMP, cyclic guanosine monophosphate; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; N-ANF, N-terminus ANF.